News
GlobalData on MSN19h
AstraZeneca’s Imfinzi approved in Europe for muscle-invasive bladder cancerThe approval comes amid speculation that the big pharma company may switch its UK stock market listing to the US.
Summit Therapeutics nears a $15B AstraZeneca deal for ivonescimab, targeting a $90B market. See more on the potential and ...
AstraZeneca is considering moving its stock market listing from London, where it is the exchange's most valuable company, to ...
AstraZeneca Plc’s shares rose after a report that Chief Executive Officer Pascal Soriot wants to move the British drugmaker’s ...
AstraZeneca’s Imfinzi receives European approval to treat patients with resectable muscle-invasive bladder cancer: Cambridge, UK Saturday, July 5, 2025, 09:00 Hrs [IST] AstraZen ...
A cautious market traded AstraZeneca stock down by more than 2% following the report, on a day when the S&P 500 index landed ...
London marked the slowest first half-year for IPO volume since 1997, a grim milestone punctuated by a report that AstraZeneca ...
AstraZeneca PLC closed 22.80% short of its 52-week high of £133.88, which the company reached on September 3rd.
By integrating foundation models into its R&D pipeline, AstraZeneca seeks to enable data-driven discovery methods.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback